title: Increased synovial fluid levels of soluble CD23 are associated with an erosive status in rheumatoid arthritis (RA).
abstract: Synovial fluid (SF) levels of soluble CD23 (sCD23) were determined in 96 patients presenting with an inflammatory knee effusion (73 with RA and 23 with reactive arthritis (ReA) serving as a control inflammatory non-erosive group) and were correlated with the degree of joint destruction, with local immune parameters (IL-1beta, IL-3, IL-4, IL-6, IL-8, IL-10, IL-12 and sCD25) and with serum markers of inflammation, C-reactive protein and erythrocyte sedimentation rate. RA patients, classified as erosive or not according to Larsen's grade, were separated as follows: (i) 13 patients with non-erosive RA; (ii) 16 RA patients with erosions in hands but not in knees, matched for disease duration with the first group; (iii) 44 RA patients with hand and knee erosions, matched with the second group for rheumatoid factor positivity but of longer disease duration. SF sCD23 levels were significantly increased in both erosive RA groups compared with non-erosive diseases, whether RA or ReA (P < 0.05), whose SF levels were not different. SF IL-10 showed a similar profile to that of SF sCD23 and was the only other parameter characteristic of erosive RA, but no direct correlation was found between the two. SF sCD23 was significantly correlated with IL-12 (r = 0.65, P = 0.0001) and sCD25 (r = 0.39, P = 0.0019) exclusively in the two erosive RA populations. In conclusion, these data showing that increased levels of sCD23 are not only found in the SF of erosive joints but also in knee SF of patients with erosive RA but without knee x-ray-diagnosed erosions suggest that this parameter might be of predictive value for joint destruction. Longitudinal studies are however needed to confirm its potential clinical interest.
authors.affiliation: Rheumatology and Haematology Departments, CHU Sart-Tilman B35, University of Liège, Liège, Belgium. Clio.Ribbens@ulg.ac.be
authors.forename: C
authors.initials: C
authors.lastname: Ribbens
authors.forename: V
authors.initials: V
authors.lastname: Bonnet
authors.forename: M J
authors.initials: MJ
authors.lastname: Kaiser
authors.forename: B
authors.initials: B
authors.lastname: Andre
authors.forename: O
authors.initials: O
authors.lastname: Kaye
authors.forename: N
authors.initials: N
authors.lastname: Franchimont
authors.forename: D
authors.initials: D
authors.lastname: de Groote
authors.forename: Y
authors.initials: Y
authors.lastname: Beguin
authors.forename: M G
authors.initials: MG
authors.lastname: Malaise
mesh_terms: D000328:Adult; D001172:Arthritis, Rheumatoid / Q000276:immunology* / Q000378:metabolism / Q000473:pathology*; D005260:Female; D005384:Finger Joint / Q000276:immunology / Q000473:pathology; D006801:Humans; D007719:Knee Joint / Q000276:immunology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D000091402:Prohibitins; D017455:Receptors, IgE / Q000378:metabolism*; D012995:Solubility; D013582:Synovial Fluid / Q000276:immunology* / Q000378:metabolism*
chemical_list: C000717331:PHB2 protein, human; D000091402:Prohibitins; D017455:Receptors, IgE